Why is Neuronetics stock surging today?
Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).
How this was made
The 30-second read
Why it matters
STIM’s pre-open surge is attributed to a decisive EPS beat versus consensus, accelerating clinic revenue, improved adjusted EBITDA, and reduced cash burn, plus leadership changes including a new CFO.
Market read
Company-specific earnings and cash-flow improvement are the dominant catalyst, with macro described as neutral ahead of tomorrow’s CPI.
What to watch
The article does not provide full guidance, margins, or longer-term cash-flow trajectory; traders may need to verify whether the cash burn improvement is sustainable beyond one quarter.
Background
The piece frames the move as a turnaround inflection, citing a Q2 2026 earnings beat and operational improvements in the Greenbrook clinic segment.
Ticker impact
Neuronetics (STIM) surged 24% pre-open after Q2 2026 results beat Wall Street on both revenue and EPS, with adjusted EBITDA near breakeven.
Bullish bias for the next session(s) as traders digest the magnitude of the EPS and EBITDA improvement versus expectations.
The article cites specific Q2 figures (revenue growth, EPS loss narrowing vs consensus, adjusted EBITDA improvement, and reduced cash burn) that directly explain the same-day surge, which typically sustains short-term follow-through unless guidance or cash-flow details disappoint.
Market effects
A strong TMS clinic segment print can improve sentiment toward interventional mental health providers and turnaround stories, though impact is likely contained to small-cap peers.
Limited, as the catalyst is company-specific and macro is described as neutral with CPI scheduled for tomorrow.
Low; no cross-border deal, regulation, or supply-chain shock is mentioned.
Counterpoint
The company still reported a net loss and only modest adjusted EBITDA, so the rally may overshoot if investors extrapolate profitability too aggressively.
Key entities
- companyNeuronetics
Interventional mental health company whose Q2 2026 results drove a 24% pre-open stock surge.
- business_segmentGreenbrook clinic segment
Primary revenue driver cited as growing 16.8% year-over-year to $26.9 million.
- personDan Reuvers
CEO quoted describing the quarter as operational progress toward sustained profitability and positive net cash flow.
